<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620981</url>
  </required_header>
  <id_info>
    <org_study_id>331-102-00088</org_study_id>
    <nct_id>NCT03620981</nct_id>
  </id_info>
  <brief_title>Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</brief_title>
  <official_title>A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week&#xD;
      treatment regimen for agitation associated with dementia of the Alzheimer's type in patients&#xD;
      who require medication, and to investigate the safety of brexpiprazole and identify the&#xD;
      optimum dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Cohen-Manfield Agitation Incentory(CMAI) score at 10 weeks</measure>
    <time_frame>Baseline, 10 weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in CMAI score at 10 weeks</measure>
    <time_frame>Baseline, 10 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Clinical Global Impression of Severity (CGI-S) score at 10 weeks</measure>
    <time_frame>Baseline, 10 weeks after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">407</enrollment>
  <condition>Agitation Associated With Dementia of the Alzheimer's Type</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole, 1mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 1mg/day Once daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole, 2mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 2mg/day Once daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo (0mg/day) Once daily for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Drug: 1 tablet /day Once daily for 10 weeks</description>
    <arm_group_label>Brexpiprazole, 1mg/day</arm_group_label>
    <arm_group_label>Brexpiprazole, 2mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 1 tablet /day Once daily for 10 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who satisfy both of the following diagnostic criteria:&#xD;
&#xD;
               1. Diagnosis of &quot;Dementia due to Alzheimer's Disease&quot; according to DSM-5.&#xD;
&#xD;
               2. Diagnosis of &quot;Probable Alzheimer's Disease&quot; according to NINCDS-ADRDA.&#xD;
&#xD;
          -  Hospitalized patients or care facility patients or care at home patients&#xD;
&#xD;
          -  Patients with an MMSE score of 1 to 22&#xD;
&#xD;
          -  Patients who have the agitation defined according to the &quot;Consensus provisional&#xD;
             definition of agitation in cognitive disorders&quot; from the International Psychogeriatric&#xD;
             Association (IPA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have dementia other than dementia of the Alzheimer's type&#xD;
&#xD;
          -  Patients diagnosed with delirium between 30 days before the screening examination and&#xD;
             baseline evaluation according to DSM-5.&#xD;
&#xD;
          -  Patients diagnosed with any of the following disorders according to DSM-5:&#xD;
&#xD;
               -  Schizophrenia spectrum and other psychotic disorders&#xD;
&#xD;
               -  Bipolar and related disorders&#xD;
&#xD;
               -  Major depressive disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Jisenkai Nanko Psychiatric Institute</name>
      <address>
        <city>Shirakawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>July 6, 2022</last_update_submitted>
  <last_update_submitted_qc>July 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

